Literature DB >> 8818344

Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

N Gozzard1, A el-Hashim, C M Herd, S M Blake, M Holbrook, B Hughes, G A Higgs, C P Page.   

Abstract

1. The effects of the inhaled corticosteroid budesonide and a novel PDE 4 inhibitor CDP840 given systematically, were evaluated in a model of antigen-induced airway inflammation in the rabbit. 2. Adult litter-matched NZW rabbits (2.4-3.5 kg) immunised within 24 h of birth with Alternaria tenuis antigen were pretreated with budesonide (total dose 100 micrograms, inhaled over 2 days) or CDP840 (total dose 7 mg kg-1, i.p. over 3 days), before antigen challenge. For each drug-treated group a parallel group of rabbits was pretreated with the appropriate vehicle. In all groups airway responsiveness to inhaled histamine was assessed and bronchoalveolar lavage (BAL) performed 24 h before and after antigen challenge. 3. Basal lung function in terms of total lung resistance (RL; cmH2O l 1s-1) and dynamic compliance (Cdyn; ml cmH2O-1) were unaltered by pretreatment with budesonide or CDP840 compared to their respective vehicles 24 h before or after antigen challenge. 4. The RL component of the acute bronchoconstriction induced by inhaled Alternaria tenuis aerosol was unaffected by pretreatment with budesonide. However, budesonide prevented the fall in Cdyn due to antigen. Treatment with CDP840 significantly reduced antigen-induced acute bronchoconstriction in terms of both RL and Cdyn. 5. Airway hyperresponsiveness (AHR) to inhaled histamine was indicated by reduced RL PC50 (2.4-4.5 fold) and Cdyn PC35 (2.1-3.9 fold) values 24 h after antigen challenge. Treatment with either budesonide or CDP840 abolished the antigen-induced increase in responsiveness to inhaled histamine. 6. Total cells recovered per ml of BAL fluid increased 24 h after antigen challenge. Antigen-induced pulmonary eosinophilia was reduced (93%) in budesonide and (85%) in CDP840 treated rabbits. Antigen-induced increases in neutrophil numbers were reduced (76%) with budesonide but not CDP840 pretreatment. 7. Inhalation of Alternaria tenuis aerosol elicited an acute bronchoconstriction, followed 24 hours later by an increased responsiveness to inhaled histamine and pulmonary neutrophil and eosinophil recruitment. CDP840 was more effective than budesonide in preventing the antigen-induced increase in total lung resistance (RL); however, both drugs prevented the antigen-induced reduction in dynamic compliance (Cdyn). CDP840 and budesonide also prevented antigen-induced AHR and eosinophilia in the immunised rabbit.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818344      PMCID: PMC1909605          DOI: 10.1111/j.1476-5381.1996.tb15524.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide.

Authors:  S M Wellicome; M H Thornhill; C Pitzalis; D S Thomas; J S Lanchbury; G S Panayi; D O Haskard
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

Review 2.  Cytokines and endothelial cell biology.

Authors:  J S Pober; R S Cotran
Journal:  Physiol Rev       Date:  1990-04       Impact factor: 37.312

3.  Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma.

Authors:  W Wiebicke; R Jörres; H Magnussen
Journal:  J Allergy Clin Immunol       Date:  1990-12       Impact factor: 10.793

Review 4.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

5.  Our changing understanding of asthma.

Authors:  P J Barnes
Journal:  Respir Med       Date:  1989-05       Impact factor: 3.415

6.  Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine.

Authors:  D W Cockcroft; K Y Murdock
Journal:  J Allergy Clin Immunol       Date:  1987-05       Impact factor: 10.793

7.  Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.

Authors:  M Holbrook; N Gozzard; T James; G Higgs; B Hughes
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

8.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

9.  Increases in airway reactivity to histamine and inflammatory cells in bronchoalveolar lavage after the late asthmatic response in an animal model.

Authors:  W R Marsh; C G Irvin; K R Murphy; B L Behrens; G L Larsen
Journal:  Am Rev Respir Dis       Date:  1985-06

10.  Airway cholinergic responsiveness in rabbits in relation to antigen sensitization and challenge.

Authors:  J W Bloom; C Baumgartener-Folkerts; J D Palmer; M Halonen
Journal:  Immunopharmacology       Date:  1988 May-Jun
View more
  6 in total

1.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Effects of dexamethasone on airway hyper-responsiveness to the adenosine A1 receptor agonist cyclo-pentyl adenosine in an allergic rabbit model.

Authors:  A Z El-Hashim; K H Banner; W Paul; C P Page
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.

Authors:  M Holbrook; N Gozzard; T James; G Higgs; B Hughes
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 5.  Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance.

Authors:  Lloyd Tanner; Andrew Bruce Single
Journal:  J Innate Immun       Date:  2019-09-17       Impact factor: 7.349

Review 6.  The rabbit as a model for studying lung disease and stem cell therapy.

Authors:  Nurfatin Asyikhin Kamaruzaman; Egi Kardia; Nurulain 'Atikah Kamaldin; Ahmad Zaeri Latahir; Badrul Hisham Yahaya
Journal:  Biomed Res Int       Date:  2013-04-08       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.